The QualityStocks Daily Tuesday, June 4th, 2019

Today's Top 3 Investment Newsletters

Epic Stock Picks (KPOC) +50.00%

StockMarketWatch (CTRM) +35.96%

MarketBeat (BAS) +30.15%

The QualityStocks Daily Stock List

MJardin Group, Inc. (MJARF)

New Cannabis Ventures, CannabisMarketCap, OTC Markets, Stockhouse, GuruFocus, Street Register, Midas Letter, Stockwatch, Marketbeat, Trading View, and NIC Investors reported earlier on MJardin Group, Inc. (MJARF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, MJardin Group, Inc. is a leader in premium cannabis production. The Company is a cannabis management platform with wide-ranging experience in cultivation, processing, distribution and retail. MJardin has more than 10 years of commercial growing experience in North America. Established in 2014, MJardin Group is headquartered in Denver, Colorado and also has an office in Toronto, Ontario.

At present, MJardin Group owns, manages or advises on a portfolio of 32 cannabis operations. The Company has refined cultivation methodologies, developed state-of-the-art facilities and implemented vertical integration for and on behalf of license owners. MJardin Group has more than 450 employees.

The Company has designed 105 cannabis facilities across 13 U.S. States, 3 Canadian Provinces and Australia. It has produced 110,000 kilograms of cannabis since 2014.

Recently, MJardin Group announced that it entered into a definitive agreement to acquire Carson City Agency Solutions, dba Cannabella, an operator of an extraction facility and producer of edibles and topicals in Carson City, Nevada. This Transaction is expected to close in Q3 2019. It will add extraction capabilities to MJardin’s present cultivation operations in Nevada, allowing the Company to use a portion of its cultivation output for extracts towards edibles, topicals and other potential product lines.

Last week, MJardin Group announced that it completed construction of “GRO”, an indoor cannabis cultivation facility located in Dunnville, Ontario. The Company has submitted its Evidence of Readiness package to Health Canada. The facility is a joint-venture (JV) between MJardin Group (75 percent) and Grand River Organics (25 percent).

The estimation is that the 11,000 square foot facility will produce 1,260 kg of premium flower and 454 kg of trim, for a total of 1,714 kg of product per year. It is expected to reach full production capacity in Q3 2019.

“GRO” is MJardin Group’s third Canadian cannabis cultivation facility to complete construction and second in Ontario as it joins “WILL”, a 32,800 square foot cultivation facility in Brampton, which was awarded its sales license in December of 2018. WILL reported yield numbers in April 2019 that surpassed MJardin’s average benchmarks over its last ten years of experience. MJardin expects to receive its cultivation license for the GRO facility by late Summer 2019.

MJardin Group, Inc. (MJARF), closed Tuesday's trading session at $1.045, up 6.91%, on 32,449 volume with 61 trades. The average volume for the last 3 months is 91,551 and the stock's 52-week low/high is $0.769/$6.684.

chart

Whiting USA Trust II (WHZT)

Zacks, Street Insider, All Stocks Today, Wallstreet Online, Stockhouse, Global Banking and Finance, Simply Wall St, Marketbeat, MarketWatch, Barchart, and Dividend Investor reported previously on Whiting USA Trust II (WHZT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Whiting USA Trust II holds a term net profits interest in the oil and gas producing properties located in the Permian Basin, Rocky Mountains, Gulf Coast, and Mid-Continent regions. Whiting USA Trust II is a subsidiary of Whiting Petroleum Corporation. The Company lists on the OTC Markets. Established in 2011, Whiting USA Trust II has its corporate office in Houston, Texas.

As of December 31, 2018, the Company’s oil and gas properties included interests in roughly 367.8 net producing oil and natural gas wells. These are situated in 46 predominately mature fields with established production profiles in 10 States.

Last month, Whiting USA Trust II announced that the Trust would make a distribution to unitholders in the second quarter of 2019. This relates to net profits generated during the first quarterly payment period of 2019. Unitholders of record on May 20, 2019 received a distribution of $0.140750 per unit that was payable on or before May 30, 2019.

The Trust’s net profits interest (NPI), the only asset of the Trust other than cash reserves held for future Trust expenses, represents the right to receive 90 percent of the net proceeds from Whiting Petroleum Corporation’s interests in certain existing oil and natural gas properties located mainly in the aforementioned Rocky Mountains, Permian Basin, Gulf Coast and Mid-Continent regions of the U.S.

As of March 31, 2019, on a cumulative accrual basis, 9.24 MMBOE (87 percent) of the Trust’s total 10.61 MMBOE have been produced and sold or divested. Based on the Trust’s reserve report for the underlying properties as of December 31, 2018, the projection is that the Trust’s 10.61 MMBOE will be produced prior to December 31, 2021, shortly after which the Trust would terminate. The 2018 year-end reserve report reflects expected annualized production decline rates of roughly 11.1 percent for oil and 23 percent for gas between 2019 and 2021.

The Company’s parent, Whiting Petroleum Corporation, is an independent oil and gas company. It develops, produces, acquires and explores for crude oil, natural gas and natural gas liquids mainly in the Rocky Mountains region of the U.S. The Company’s largest projects are in the Bakken and Three Forks plays in North Dakota and Montana and the Niobrara play in northeast Colorado.

Whiting USA Trust II (WHZT), closed Tuesday's trading session at $1.31, even for the day, on 11,390 volume with 19 trades. The average volume for the last 3 months is 42,248 and the stock's 52-week low/high is $1.00/$3.16.

chart

Sharp Corporation (SHCAY)

Small Cap Network, Earnings Whispers, Emerging Growth, Marketbeat, Stockwatch, MarketWatch, Stockhouse, Wallmine, Market Screener, Wallet Investor, Zacks, Real Investment Advice, and Investors Place reported earlier on Sharp Corporation (SHCAY), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A Japanese multinational corporation, Sharp Corporation designs and manufactures electronic products. Its business activities primarily consist of the manufacturing and sales of telecommunications equipment, electric and electronic application equipment, and electronic components. The Company operates through four segments. These are Smart Homes, Smart Business Solutions, Internet of Things (IoT) Electronics Devices, and Advance Display Systems. Established in 1912, Sharp has its corporate office in Sakai City, Osaka, Japan.

The Company’s main products for the Smart Homes segment includes mobile phones, electronic dictionaries, calculators, telephones, network control units, refrigerators, superheated steam ovens, washing machines, vacuum cleaners, air purifiers, fans, dehumidifiers, humidifiers, Plasmacluster ion generators, beauty equipments, solar cells, storage batteries, and personal computers among many others. Products for the Smart Business Solutions segment include multi function printers, information displays, POS system equipments, electronic registers, business projectors, various options/ consumables, and varied software.

Sharp’s products for the IoT Electronics Devices segment include camera modules, camera module manufacturing facilities, sensor modules, proximity sensors, dust sensors, wafer foundry, CMOS/CCD sensors, semiconductor lasers, in-vehicle cameras, FA equipments, and washing machines, among others. Moreover, the Company’s products for the Advance Display Systems segment include LCD TVs, Blu-ray disc recorders, audio equipment, and display modules, among more. All of the products represent Sharp’s product family as of March 31, 2019.

In 2018, Sharp released the AQUOS R2, the world’s first smartphone (as of May 8, 2018, based on Sharp research. For a smartphone with two rear cameras that can take photos with the still-image camera while shooting video with the video camera) to have two cameras - one for shooting videos and the other for taking photos - on the back (in addition to two rear cameras, the R2 has a front-facing camera). This inventive configuration allows one to take videos and photos simultaneously.

The R2’s video camera (named Dramatic Wide Camera) has an ultra-wide-angle lens featuring a 135-degree field of view. The photo camera has 22.6 megapixels. While shooting video, the R2’s artificial intelligence (AI) analyzes the object and the shot composition. It can automatically take photos of memorable scenes while shooting video.

Sharp Corporation (SHCAY), closed Tuesday's trading session at $2.27, up 5.09%, on 197,246 volume with 114 trades. The average volume for the last 3 months is 132,895 and the stock's 52-week low/high is $2.15/$6.64.

chart

Harvest Health & Recreation, Inc. (HRVSF)

Cannabis Business Times, Micro Cap Daily, New Cannabis Ventures, Stockhouse, Proactive Investors, InvestorsHub, Midas Letter, Cannabis Stock Trades, Profit Confidential, and Market Watch reported previously on Harvest Health & Recreation, Inc. (HRVSF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

A vertically-integrated cannabis company, Harvest Health & Recreation, Inc. has one of the largest and deepest footprints in the U.S. It is a multi-state cannabis operator (MSO). The Company’s corporate mission is to improve lives through the goodness of cannabis. Harvest Health & Recreation is focused on its vision to become the most valuable cannabis company worldwide. OTCQX-listed, the Company is headquartered in Tempe, Arizona.

Harvest Health & Recreation’s total vertical solution includes industry-leading cultivation, manufacturing, and retail facilities, construction, real estate, technology and operational expertise -leveraging in-house legal, human resources and marketing teams, along with proven experts in writing and winning State-based applications. Since 2011, its commitment has been to aggressively expanding its Harvest House of Cannabis retail and wholesale presence across the U.S., acquiring, creating and growing leading brands for patients and consumers nationally, and continuing on a course of profitable growth.

Subject to the completion of announced acquisitions, Harvest Health & Recreation will have the largest footprint in the U.S., with rights to 219 facilities, of which 142 are retail locations and over 1,580 employees across 17 States. The Company now operates or has rights to operate in cannabis facilities or expects to have rights to acquire licenses following the closings of earlier announced acquisitions in Arizona, Arkansas, California, Delaware, Florida, Illinois, Maryland, Massachusetts, Michigan, New Jersey, Nevada, North Dakota, Ohio, Oklahoma, Pennsylvania and Puerto Rico.

Harvest Health & Recreation announced this past April that it entered into a binding, definitive agreement to acquire CannaPharmacy, Inc., subject to satisfaction of customary closing conditions. This includes receipt of regulatory approvals in the relevant States. CannaPharmacy owns or operates (through management companies) cannabis licenses in Pennsylvania, Delaware, New Jersey, and Maryland. It also holds a minority interest in a pending licensee in Colombia. Harvest Health & Recreation expects that the transaction will be accretive to the Company’s 2020 revenue and EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization).

Harvest Health & Recreation would become the largest MSO in the U.S. following closing of a definitive agreement signed on April 22, 2019 to acquire Verano Holdings, LLC, as earlier announced by a press release dated March 11, 2019. Verano Holdings is one of the largest privately held multi-state, vertically integrated licensed operators of cannabis facilities with a broad portfolio of premium branded products.

Today, Harvest Health & Recreation announced the signing of an agreement to bring their popular Colors, CBx Essentials and Harvest-branded CBD product lines to over 10,000 retail stores. This includes convenience stores and gas stations throughout the nation. The multi-million-dollar partnership, which will roll out to the Asian American Trade Associations Council (AATAC) retailer network brings top CBD products with considerable demand to a system of every day strategic markets in small towns and major metropolitan regions.

Harvest Health & Recreation Chairman, Mr. Jason Vedadi, said, “This exclusive partnership enables a massive advance in distribution for Harvest-owned CBD brands and follows our strategic path of expanding the scale of our wholesale and retail distribution nationally. Demand for CBD is unprecedented and by delivering leading products in 10,000 accessible locations gives us an unparalleled reach to consumers.”

Harvest Health & Recreation, Inc. (HRVSF), closed Tuesday's trading session at $6.2384, down 3.43%, on 756,001 volume with 1,729 trades. The average volume for the last 3 months is 427,671 and the stock's 52-week low/high is $0.075/$10.85.

chart

Innovus Pharmaceuticals, Inc. (INNV)

NetworkNewsWire, Zacks, Street Insider, Micro Cap Daily, StreetWise Reports, Marketbeat, OTC Markets, Stockaholics, Insider Financial, GlobeNewswire, Simply Wall St, 4-Traders, Stockhouse, and Stockwatch reported earlier on Innovus Pharmaceuticals, Inc. (INNV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Innovus Pharmaceuticals, Inc. is an emerging commercial-stage pharmaceutical company listed on the OTCQB Venture Market. Innovus delivers safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men’s and women's health and respiratory diseases. The Company’s commitment is to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (ANDA) products. Established in 2008, Innovus Pharmaceuticals has its corporate office in San Diego, California.

Innovus is pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (Rx) to OTC. The Company delivers innovative and uniquely presented and packaged health solutions via its OTC medicines and consumer and health products that it markets directly, via commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers via its on-line channels, retailers and wholesalers.

Innovus Pharmaceuticals has products for a range of indications. These include Brain Health, Diabetes, Fertility, Men’s Health, Pain Management, Respiratory, Vitality, Vision, and Women’s Health.

Last week, Innovus Pharmaceuticals announced that it received the CPNP notification number required to commercialize Diabasens® in all 28 member countries of the European Union (EU). This represents the fourth Innovus product to receive CPNP notification in the EU in the last few years, the others being for Zestra®, Zestra Glide® and Sensum+®. This product will be available as an OTC or behind the counter product. It does not require a prescription.

Today, Innovus Pharmaceuticals announced that it entered into a supply relationship with a third party to supply the Company with omeprazole 20mg tablets and omeprazole 20mg 24 hour delayed release capsules indicated for the treatment of frequent heartburn under the approved abbreviated new drug application (ANDA) No. 207891 from the U.S. Food and Drug Administration (FDA). Innovus will launch the drug under its own trademark OmepraCare™ 20mg tablets and OmepraCare™ DR 20mg 24 hour delayed release capsules.

Innovus Pharmaceuticals, Inc. (INNV), closed Tuesday's trading session at $2.05, up 7.33%, on 4,870 volume with 17 trades. The average volume for the last 3 months is 29,464 and the stock's 52-week low/high is $1.50/$19.37.

chart

Kona Gold Solutions, Inc. (KGKG)

Micro Cap Daily, Talkmarkets, Trading View, Market Screener, 4-Traders, Discovery Stocks, Insider Financial, Stockwatch, Stockhouse, Clay Trader, InvestorsHub, Wallet Investor, Wallmine, and Dividend Investor reported earlier on Kona Gold Solutions, Inc. (KGKG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kona Gold Solutions, Inc. is a hemp and CBD lifestyle brand focused on product development in the functional beverage sector. The Company has created wholly-owned subsidiaries, Kona Gold LLC, HighDrate, LLC, and Gold Leaf Distribution, LLC. Kona Gold Solutions has its head office in Melbourne, Florida. The Company lists on the OTC Markets.

Subsidiary Kona Gold, LLC has developed a premium Hemp Infused Energy Drink line. The HighDrate, LLC subsidiary has developed the beverage industry’s first CBD Energy Water, available in four flavors. The Gold Leaf Distribution, LLC subsidiary was created to fill Kona Gold Solutions’ distribution needs in markets it wants to rapidly enter.

Kona Gold Solutions announced this past April it started production of its new Hemp Energy Drink and CBD Energy Water flavors. Its Kona Gold Hemp Energy Drink line extension includes Bubble Gum and Candy Apple flavors. The line extension for its HighDrate CBD Energy Waters includes Blue Island Punch and Sour Apple.

The Company has been working over the last number of months with its world class formulators to create new flavors that will complement and play off of Kona Gold’s already successful flavor line up and will resonate with the Company’s consumers.

Kona Gold Solutions has recently partnered with sixteen new distributors. The new distribution partners are in California, Idaho, Indiana, Kentucky, Louisiana, Minnesota, Nevada, New Mexico, New York, Oklahoma, Texas, Virginia, Washington, and Wisconsin. Currently, the Company has distribution partners in 24 States.

In May, Kona Gold Solutions announced it signed an LOI (Letter of Intent) to lease warehouse space in Greer, South Carolina, right outside of Greenville. The warehouse covers 30,000 square feet, in which Kona Gold will acquire 15,000 square feet with the option to lease the additional 15,000 square feet within two years. The new warehouse space will operate as the Company’s distribution hub, where all product will be stored and shipped to distributors across the nation. Additionally, the location will serve as a new Gold Leaf Distribution hub as Kona Gold expands Gold Leaf’s distribution footprint in new markets.

Also in May, Kona Gold Solutions announced it signed a distribution agreement with Savannah Distributing Company, Inc. Savannah Distributing Company, based in Savannah, Georgia, placed an initial order of Kona Gold Energy Drinks.

Last week, Kona Gold Solutions announced it launched its highly anticipated Bubble Gum and Candy Apple flavored hemp energy drinks. The announcement is coming off the success of Kona Gold’s new Cotton Candy and Cherry Vanilla flavors, which went to market in late 2018 and continue to be the Company’s top selling hemp energy drinks.

                   

Kona Gold Solutions, Inc. (KGKG), closed Tuesday's trading session at $0.135, down 2.17%, on 6,846,311 volume with 687 trades. The average volume for the last 3 months is 9,099,042 and the stock's 52-week low/high is $0.007/$0.149.

chart

Medicure, Inc. (MCUJF)

Zacks, Stockhouse, StockEarnings, Barchart, Private Capital Journal, Stockwatch, Streetwise Reports, Morningstar, Marketbeat, and StockScores reported previously on Medicure, Inc. (MCUJF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A pharmaceutical company, Medicure, Inc. concentrates on the development and commercialization of therapies for the U.S. cardiovascular market. The Company’s current emphasis is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAGTM (pitavastatin) tablets and the ReDS™ device in the U.S., where they sell through the Company's U.S. subsidiary, Medicure Pharma, Inc. Founded in 1997, Medicure has its corporate headquarters in Winnipeg, Manitoba. The Company lists on the OTC Markets.

Medicure is a U.S focused Specialty Pharma company with established sales of Aggrastat. The Company carefully monitors opportunities within its own pipeline of products and possible acquisitions of related pharmaceutical companies in order to achieve long term value.

Medicure’s subsidiaries include Medicure International, Inc. (Barbados), which owns the U.S. rights to AGGRASTAT, and also two U.S. corporations, Medicure USA, Inc. and Medicure Pharma, Inc., which distribute the Company's products in the U.S.

In May, Medicure announced the appointment of Ms. Manon Harvey CPA, CA, to the Board of Directors. Ms. Harvey is a CPA, CA, and holds a Bachelor of Commerce (summa cum laude) from the University of Ottawa . Additionally, she has her ICD.D designation from the Institute of Corporate Directors. This past January, she joined the University of British Columbia's Okanagan Campus as Director, Integrated Planning and Chief Budget Officer. Ms. Harvey is an external member of the Departmental Audit Committee of the Royal Canadian Mounted Police.

Last week, Medicure reported its results from operations for the quarter ended March 31, 2019. The Company Recorded Net Revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $4.8 million during the quarter ended March 31, 2019 versus $6.1 million for the quarter ended March 31, 2018.

Medicure continued to experience strong patient market share held and strong hospital demand for AGGRASTAT® during the three months ended March 31, 2019. However, increases in volume versus the three months ended March 31, 2018 were offset by increased price competition, which resulted in lower discounted prices for AGGRASTAT® throughout the quarter.

Medicure, Inc. (MCUJF), closed Tuesday's trading session at $4.04, up 5.48%, on 100 volume with 1 trade. The average volume for the last 3 months is 1,057 and the stock's 52-week low/high is $3.7716/$5.778.

chart

Petrogress, Inc. (PGAS)

NetworkNewsWire, Marketbeat, Last10k, MarketWatch, Whale Wisdom, OilandGas360, Trading View, Investors Hangout, Stockhouse, Stockwatch, StockInvest, Barchart, 4-Traders, YCharts, Wallet Investor, Simply Wall St, GuruFocus, Stockopedia, and Dividend Investor reported earlier on Petrogress, Inc. (PGAS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Petrogress, Inc., by way of its subsidiaries, operates as an integrated merchant of petroleum products. The Company is an independent Oil energy and Shipping company. It specializes in oil exploration, production, trade and sea transportation with global operations throughout Europe, Africa and the Middle East. The Company owns and operates a fleet of tankers from its base in the historic Port of Piraeus through a series of Marshall Islands subsidiaries. Petrogress is based in Delaware and New York and lists on the OTC Markets.

The Company operates mainly as a holding company for its wholly-owned subsidiaries. Petrogress concentrates on the supply and trade of light petroleum fuel oil, refined oil products and other petrochemical products to local refineries in West Africa and Mediterranean countries.

In addition, Petrogress operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. The Company is actively looking for expansion opportunities. This includes in operating and developing natural gas production and transmission facilities along with LNG processing in the United States, refinery operations in north and West Africa, and the transport and sales of LNG in Europe.

For Upstream - oil resources and exploration, Petrogress has its Petrogres Oil & Gas Energy, Inc. subsidiary. For Midstream - product fleet carriers, the Company has its Petronav Carries, LLC subsidiary. Regarding Downstream – processing and refining, it has its J/V PGO & PGL – Ghana subsidiary. Furthermore, regarding Marketing – purchases and sales, Petrogress has its Petrogres Co. Limited subsidiary.

In December of 2018, Petrogress announced that its Petrogress Int’l, LLC (PIL) subsidiary entered into a Partnership Agreement with Deliman Oil Company Limited, a Ghanaian corporation. This Agreement is to jointly create and co-operate a Ghanaian corporation to be called PG&D Fueling. PG&D will operate and manage gas/refueling stations in Ghana, Burkina Faso and Niger and associated storage and distribution operations.

The expectation is that PG&D will initially operate and manage 65 gas stations now owned by Deliman in Ghana and Burkina Faso. The petrochemical products to be distributed via PG&D managed gas stations will be supplied by PIL affiliate company Petrogres Co. Limited, via its partnership with Platon Oil Refinery in Ghana.

Recently, Petrogress announced that its PIL subsidiary entered into an Exclusive Distribution Agreement with Dana Lubricants Factory LLC (Dana Lubes), a United Arab Emirates (UAE) based lubricant oil manufacturer. This agreement designates PIL as the exclusive agent for distribution of products manufactured and branded by Dana Lubes throughout western Africa.

Petrogress, Inc. (PGAS), closed Tuesday's trading session at $1.99, up 6.80%, on 3,620 volume with 9 trades. The average volume for the last 3 months is 2,862 and the stock's 52-week low/high is $0.006/$2.09.

chart

Covalon Technologies Ltd. (CVALF)

4-Traders, InvestorsHub, Stockhouse, Morningstar, Stockwatch, Barchart, OTC Markets, TradingView, InvestorsHangout, Proactive Investor, Penny Stock Picks, Penny Stock Tweets, MarketWatch, The Street, GuruFocus, Wallet Investor, and Capital Cube reported earlier on Covalon Technologies Ltd. (CVALF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Covalon Technologies Ltd. is an advanced medical technologies company headquartered in Mississauga, Ontario. Covalon researches, develops and commercializes new healthcare technologies. The Company’s patented technologies, products, and services address the advanced healthcare needs of medical device companies, healthcare providers, and individual consumers. Covalon Technologies lists on the OTC Markets’ OTCQX.

Covalon’s technologies are used to prevent, detect and manage medical conditions in specialty areas including wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. Its Advanced Wound Care line has been specifically designed for the successful treatment of a wide variety of wounds.

The Company has its CovaWound™ and ColActive® brands. It has its ColActive® Plus Collagen Matrix Dressing; ColActive® Plus Ag Collagen Matrix Dressing With Silver; and ColActive® Transfer Wound Contact Layer. It also has its Covalon IV Clear™ Antimicrobial Clear Silicone Adhesive Securement Dressing With Chlorhexidine And Silver.

The Company’s Perioperative Care brands, MediClear™ and SurgiClear™ offer a range of care throughout a patient’s surgical journey. The Company has its Technology platforms. These are its Biomatrix Platform, its Antimicrobial Silicone Platform, and its Medical Coating Platform.

Pertaining to Infection Prevention, Covalon Technologies has its highly lubricious and first-rate antimicrobial protection SilverCoat™ Foley catheter. Furthermore, the Company has its dual antimicrobial silicone adhesive platform across the MediClear™ PreOp, SurgiClear™ and IV Clear™ brands.

Covalon Technologies has acquired AquaGuard. This is the Seattle, Washington-based division of medical technologies company Cenorin, LLC. AquaGuard's specialized products provide patients with vital moisture protection for wound, surgical, and vascular access sites throughout the body while showering. The Company’s efforts to enter the European and Latin American markets are expected to begin to contribute to its revenue in fiscal 2019.

Covalon Technologies’ Q1 Fiscal 2019 Revenue was in line with expectations at $7.2 million. This represents a 13 percent increase versus last year. The expectation is that Fiscal 2019 contracted Middle East revenue will be roughly $30 million, more than double the contracted revenue of fiscal 2018. Fiscal 2019 revenue in the U.S. is on course to surpass $25 million.

Q1 Fiscal 2019 Gross Profit was 63 percent versus 71 percent in Q1 fiscal 2018. Net Loss was $1.9 million or $0.09 per share, versus a profit of $0.5 million or $0.02 per share (diluted) in Q1 fiscal 2018.

Q1 Fiscal 2019 Net Income included roughly $1.0 million of acquisition costs, accretion, interest, and purchase accounting expenses associated with the acquisition of AquaGuard incurred during the quarter. No similar costs were incurred in the prior year’s Q1.

Covalon Technologies Ltd. (CVALF), closed Tuesday's trading session at $3.9425, up 10.90%, on 4,600 volume with 16 trades. The average volume for the last 3 months is 1,443 and the stock's 52-week low/high is $2.55/$7.12.

chart

NaturalShrimp, Inc. (SHMP)

Wall Street Analyzer, Uptick Newswire, OTC Dynamics, InvestorsHub, MicroCapDaily, Trading View, The Penny Picks, Insider Financial, MarketWatch, Equities, PR Newswire, SmallCapVoice, Born2Invest, Last10k, Morningstar, Market Screener, Barchart, Morningstar, Pennystockmania, Wallet Investor, YCharts, PennyPickGains, WallstreetSurfers, Investors Hangout, and The Street reported previously on NaturalShrimp, Inc. (SHMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

NaturalShrimp, Inc. is an international leader in aquaculture technology. The OTCQB-listed Company has developed and tested the first commercially-viable system for growing shrimp indoors. This system uses a proprietary technology to reliably produce healthy, naturally-grown shrimp weekly without the use of antibiotics or toxic chemicals. NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp dependably and economically in an indoor, re-circulating, saltwater facility.

NaturalShrimp is headquartered in Dallas, Texas. The Company’s production facility is outside of San Antonio, Texas. NaturalShrimp, Inc. owns 100 percent of NaturalShrimp Corporation, established to operate in the United States and Canada, and 100 percent of NaturalShrimp Global, Inc., established to form International Joint Venture (JV) Partnerships.

NaturalShrimp operates a closed-system saltwater aquaculture facility. This facility produces high-grade Pacific White shrimp. It accomplishes this without using the antibiotics and chemical additives today’s shrimp farms require. The technology causes ammonia (NH3) to break down into risk-free nitrogen and hydrogen gas. As a result, this eliminates one of the historically most demanding problems in shrimp aquaculture.

NaturalShrimp’s eco-friendly, bio-secure design does not depend on ocean water. It recreates the natural ocean environment allowing for high-density production, which can undergo replication anywhere worldwide. The NaturalShrimp Automated Monitoring and Control system utilizes individual tank monitors to automatically control the feeding, oxygenation, and the temperature of each of the facility tanks independently. In addition, a facility computer, running custom software, communicates with each of the controllers and performs more data acquisition functions that can report back to a supervisory computer from anywhere globally.   

NaturalShrimp has installed an enhanced version of its vibrio suppression technology system at the La Coste, Texas production facility. The design of the Company's vibrio suppression technology is to create higher sustainable shrimp population densities, consistent production, improved growth, higher survival rates, and first-rate food conversion in an all-natural ocean-type environment.

Recently, NaturalShrimp announced that NaturalShrimp and F&T Water Solutions, LLC received U.S. Patent No. 10,163,199 B2 for the Recirculating Aquaculture System and Treatment Method for Aquatic Species developed for the first commercially viable system for growing aquatic species indoors.  NaturalShrimp maintains the exclusive global rights for any and all shrimp species using this patent dated December 25, 2018.

NaturalShrimp also recently announced that it completed testing its patented technology to grow shrimp indoors with Shrimp Lot 180. Mr. Bill G. Williams, Chairman and Chief Executive Officer, said, “The method worked extremely well and maintained the water control parameters within acceptable limits through the grow-out period.”

NaturalShrimp, Inc. (SHMP), closed Tuesday's trading session at $0.11, up 6.80%, on 2,756,263 volume with 374 trades. The average volume for the last 3 months is 4,584,069 and the stock's 52-week low/high is $0.005/$0.949.

chart

FogChain Corp. (FOGCF)

StockReads, Stock Orange, Stockwatch, Bullish Guru, Penny Stock Hub, Press Reader, Investors Hangout, 4-Traders, OTC Markets, InvestorsHub, MarketWatch, Barchart, Insider Financial, Stockhouse, TradingView, Market Screener, and Wallet Investor reported previously on FogChain Corp. (FOGCF),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

FogChain Corp. is a completely integrated, end-to-end software development life cycle (SDLC) and quality assurance solutions provider. The Company’s set of services and technology provides application development at scale with more speed, efficiency and at a lesser cost. FogChain's Build-Once Deploy-Everywhere software architecture provides developers with a set of tools and resources that bridges devices, operating systems, and the ability to build and launch new applications in a unified environment. OTCQB-listed, FogChain is based in Vancouver, British Columbia.

FogChain has acquired RadJav, which provides developers with fast application development tools and resources for the creation of mobile and web apps, smart contracts, and dApps. These are to be used across all major operating systems and devices on a unified platform. In addition, FogChain also acquired Quilmont - a growing and profitable software development solutions provider specializing in automated testing, Continuous Integration and Deployment (CI/CD), mobile and website development, and software quality assurance.

Fundamentally, FogChain provides a next generation platform. This platform seamlessly integrates application development and deployment that leverages a high-performance Fog (or Edge) based computing network to drive scale and connects with the unique and ground-up built RadJav Blockchain. FogChain is introducing the next generation of decentralized compute to the world of software development and application lifecycle management.

RadJav has completed the integration of Visual Studio Code (VS Code) into its platform. The RadJav platform provides fast application development tools and resources to build and launch applications across all devices, from PCs to tablets and smartphones, and also operating systems such as Linux, Windows, Mac OSX, and Apple's iOS - all using the same code.

Fog Computing utilizes decentralized and distributed computing resources and application services that are closer to the Edge, or actual point of use. Fog Computing integrates with the most current technologies. These include IoT (Internet of Things), Blockchain, 3D & Virtual Reality engines, and analytics tools. It can leverage underused resources, reducing costs.

FogChain announced this past November that it commercialized and launched its Automated Application Testing Platform, Test Case Manager (TCM), an enterprise grade software application testing solution. TCM is a patented automated testing product. It enables organizations to accomplish substantial cost savings and improved time to market through automating their test cases.

FogChain also reached an agreement to acquire AppMark's application monitoring and benchmarking platform (AppMon) and other related assets for the issuance of one million shares and $40,000 USD. AppMark (Redwood City, California) is a SaaS solutions provider. It specializes in synthetic performance monitoring of enterprise mobile, web, as well as desktop applications.

Recently, FogChain announced it completed work on an initial release of Trident. This is a unified cross-platform application development, testing and monitoring services platform. Trident's Build-Once-Deploy-Everywhere software architecture provides developers with a group of tools to build, test, and monitor new applications using a single code-base while being natively deployed across desktop, tablet, and mobile devices.

Trident will feature the ability to deploy virtual testing labs across an array of web browsers and all major operating systems. The containerized approach permits companies to scale their development, testing, and monitoring processes with minimal effort and considerable cost savings.

FogChain Corp. (FOGCF), closed Tuesday's trading session at $0.0436, up 9.00%, on 127,550 volume with 5 trades. The average volume for the last 3 months is 9,980 and the stock's 52-week low/high is $0.0316/$0.364.

chart

Investview, Inc. (INVU)

Stock Deputy, Morningstar, Stockopedia, Stockflare, Investopedia, Stockhouse, MarketWatch, Barchart, InvestorsHub, Marketwired, last10k, Infront Analytics, Capital Cube, OTC Markets, The Street, Proactive Investors, Trading View, Stockwatch, and Guru Focus reported earlier on Investview, Inc. (INVU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Investview, Inc. is a diversified financial technology company based in Salt Lake City, Utah. It operates primarily through its wholly- and majority-owned subsidiaries. Investview provides financial products and services to accredited investors, self-directed investors, and select financial institutions. The Company has its Wealth Generators wholly-owned subsidiary that has undergone a name change. Investview lists on the OTCQB.

Investview announced in March of 2018 that it filed a name change for its wholly-owned subsidiary Wealth Generators LLC to Kuvera LLC. Investview changed the name of Wealth Generators to Kuvera LLC in its first steps to create its vision for its previously acquired LLC. Investview released the Kuvera brand in the final transition steps to rename its wholly-owned subsidiary Wealth Generators LLC to Kuvera LLC. Investview completed the transition on April 12, 2018 when it unveiled the Kuvera brand through a series of live launch webinars, the release of kuveraglobal.com and a complete set of marketing tools to share the Kuvera vision and mission.  

In essence, Investview provides education and technology designed to help individuals in navigating the financial markets. Its services include tools and research, newsletter alerts, and live education rooms that consist of instruction on the subjects of equities, options, FOREX, ETF’s, and binary options.

The Company also offers education and technology applications to help individuals in debt reduction, enhanced savings, budgeting, and proper tax expense management. Investview has added Crypto mining services and education to its program services.

Investview entered into an agreement with BYOBitcoin LLC. This agreement is to provide mining hardware, software and services for Bitcoin mining. Investview’s ability to provide a turn-key hardware and services package permits individuals to participate in what has become a technology sector primarily controlled by large players who can establish huge mining farms.

Investview officially launched Kuvera France in Paris on Sunday, January 6, 2019. Kuvera France is a wholly-owned subsidiary of Investview that was established in late 2018 to handle the considerable demand for Kuvera financial education products in the European Union (EU), with the strongest demand in France.

Investview has entered a definitive material agreement with Triton Funds, LP in a strategic financial arrangement that enables growth and expansion for the Company’s financial product education used mainly by millennials. On December 29, 2018, Investview entered into a Common Stock Purchase Agreement, a Registration Rights Agreement, and a Share Donation Agreement with Triton Funds, LP, a Delaware Limited Partnership, a non-affiliate of the company.

Since inception, the overwhelming majority of the Kuvera customer base is millennials. Kuvera’s growth is stimulated by this demographic and the Company’s top distributors are under the age of 30. Kuvera provides affordable access to valuable financial education, current market research and leading-edge technology. Kuvera products undergo distribution by way of a direct sales model. Product services are offered to individuals on a monthly subscription basis.

Moreover, Investview has entered the automated trading industry via its wholly-owned subsidiary SAFE Management LLC. Investview entered the trade automation space with the launch of two new robo trading products offered through its wholly-owned Registered Investment Advisor: Safe Management, and made available to customers of Kuvera financial education services.

Investview, Inc. (INVU), closed Tuesday's trading session at $0.02573, up 38.48%, on 338,875 volume with 25 trades. The average volume for the last 3 months is 634,360 and the stock's 52-week low/high is $0.004/$0.0675.

chart

Isodiol International, Inc. (ISOLF)

SmallCapPower, Investors News, OTC Markets, Wallet Investor, Barchart, MarketWatch, Investopedia, Stockhouse, Stockwatch, Morningstar, Trading View, Wealth Daily, Investing News, MicroSmallCap, Proactive Investors, The Street, InvestorsHub, and GuruFocus reported earlier on Isodiol International, Inc. (ISOLF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Isodiol International, Inc. specializes in the development of pharmaceutical and wellness products. Its growth strategy includes the development of Over-the-Counter (OTC) and pharmaceutical drugs and expanding its phytoceutical portfolio. Be Trū Wellness is a wholly-owned subsidiary of the Company. Isodiol is continuing international expansion into Latin America, Asia, and Europe. A global CBD innovator and OTCQB-listed, Isodiol International is headquartered in Vancouver, British Columbia.

Isodiol International specializes in hemp-based health and wellness products and the development of pharmaceutical CBD delivery methods. In addition, the Company specializes in the manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in finished pharmaceutical products (FPPs).

Isodiol is the market leader in pharmaceutical grade phytochemical compounds. It is also the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol produces raw ingredients, consumer packaged goods, including dietary supplements, food and beverages, skin care, and pharmaceutical products for the worldwide healthcare market.

Regarding raw ingredients, Isodiol develops natural phytoceutical derivatives and delivery technologies. Additionally, it develops white label products and brands for wholesale customers. Concerning pharmaceuticals, the Company supplies raw phytoceutical ingredients. Pertaining to consumer products, it develops its own family of product brands for retail sale.

Isodiol has its ImmunAG™. This product is the market’s first non-cannabis cannabidiol (CBD) product derived from the hops plant. This is a time-released tablet. The ImmunAG tablet does not dissolve in the stomach. It dissolves in the lower intestine, thus creating greater bioactivity.

Isodiol has acquired global licensing rights for IsoDerm™ and five other proprietary pharmaceutical compounds to be delivered by the patented Direct Effects Technology™. This is a back of the neck delivery system from its developer Dr. Ronald Aung-Din, MD.

Recently, Isodiol International announced the acquisition of the CBD Naturals® beverage brands and intellectual property (IP) portfolio. This includes Hemp Rain, Rasa, Bliss Me, Fast CBD, and Simplex. This deal includes additional financing from the Company’s founder, Jared Berry, to be used for guaranteed product placement in greater than 1,000 U.S. retail locations. The transactions include the transfer to Isodiol International’s subsidiaries of substantially all of the IP and inventory of Carlsbad Naturals LLC, a Wyoming limited liability company (Carlsbad WY), and Carlsbad Naturals LLC, a New Mexico limited liability company (Carlsbad NM).

Isodiol International, Inc. (ISOLF), closed Tuesday's trading session at $0.8551, up 0.61%, on 142,083 volume with 137 trades. The average volume for the last 3 months is 134,633 and the stock's 52-week low/high is $0.7485/$6.00.

chart

Digerati Technologies, Inc. (DTGI)

Emerging Growth, Zacks, MarketWatch, Stockhouse, Real Investment Advice, OTCPicks, AllPennyStocks, GuruFocus, MicrocapVoice, Equities, Marketwired, SmallCapVoice, The Street, InvestorsHub, Stockopedia, Wallet Investor, and Morningstar reported earlier on Digerati Technologies, Inc. (DTGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Digerati Technologies, Inc. is a diversified holding company listed on the OTC Markets’ OTCQB. It has subsidiary operations in the cloud communications industry. The Company, via its  wholly-owned  subsidiary, Shift8 Technologies, Inc., provides Internet-based telephony products and services through its cloud telephony application platform and session-based communication network. is headquartered in San Antonio, Texas.

Fundamentally, the Company is an established and award-winning provider of cloud communication services. It serves traditional carriers, telephony resellers, as well as other VoIP  (Voice over Internet Protocol) carriers in the United States and worldwide. Digerati Technologies provides VoIP communication services to telecommunications companies.

Digerati Technologies completed the acquisition of Synergy Telecom, Inc. in 2017. Digerati’s Shift8 Networks combined Synergy Telecom with its Texas-based business and operations. Synergy Telecom is a foremost provider of cloud communication services in Texas.

In 2018, Digerati Technologies completed the acquisition of T3 Communications, Inc. It stated that this acquisition positions Digerati for hyper-growth in two of the fastest growing sectors of the telecommunications industry, UCaaS (Unified Communications as a Service) and SD-WAN (Software-Defined Wide-Area Network). T3 Communications is a top provider of cloud communications and broadband solutions in Southwest Florida.

Digerati’s Shift8 Networks subsidiary is an enterprise hosted PBX and cloud-based Unified Communications service provider. Shift8 Networks provides voice, video, and mobile communications to thousands of businesses via its Channel Alliance program.

Shift8 integrates hosted VoIP with cloud-based messaging and desktop applications. Its VAR program targets PBX Vendors, Information Technology (IT) Services firms, Managed Service Providers, and Systems Integrators that lack a cloud telephony infrastructure, but have an embedded customer base that needs Internet-based telephony services.

Digerati also provides Internet-based services. These include  fully hosted IP/PBX services, IP trunking; call center applications, prepaid services, and interactive voice response auto attendant. Services additionally include call recording, simultaneous calling, voicemail to email conversion, and many customized IP/PBX features in a hosted or cloud environment for specialized applications. 

Digerati has launched a mobile ‘business continuity’ solution in partnership with Otarris, a division of Kajeet, Inc., for addressing the increasing demand for disaster recovery networks in the enterprise marketplace. Digerati is addressing the growing need for its customers to deploy a redundant and diverse bandwidth solution for ‘business continuity’ during primary network outages. These include those caused by natural or human-induced disasters.

Recently, Digerati Technologies announced that it entered into an agreement to acquire a minority ownership stake in Itellum Comunicaciones Costa Rica S.R.L. Itellum is a fully licensed telecommunication and Internet Service Provider. With this agreement, Digerati expands its long-standing relationship with Itellum, a regional Partner and VAR (Value-Added Reseller) for its cloud communication services. Digerati's purchase of a minority stake secures Itellum as the exclusive provider of Digerati's services. It also positions Digerati Technologies to better serve Central America.

Digerati Technologies, Inc. (DTGI), closed Tuesday's trading session at $0.211, up 0.09%, on 20,310 volume with 11 trades. The average volume for the last 3 months is 57,509 and the stock's 52-week low/high is $0.07/$0.57.

chart

The QualityStocks Company Corner

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands, Inc. (CSE: GGB) (OTCQB: GGBXF) ("GGB" or "the Company") announced that on Monday, June 3, 2019, it executed an arm's length definitive agreement to acquire all of the issued and outstanding shares of capital stock of Spring Oaks Greenhouses, Inc. ("Spring Oaks"). Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Additionally, the company was highlighted in an article examining how the cannabis industry has seen an explosion of mergers and acquisitions over the past year. Major companies have been competing amongst each other for the most attractive deals, often paying premiums in the process to make their offers more appealing.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $2.646, up 12.86%, on 671,191 volume with 899 trades. The average volume for the last 3 months is 255,236 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) was named today as among the companies featured on the newly announced OTCQX Cannabis Index, from OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.4651, off by 0.45%, on 143,404 volume with 72 trades. The average volume for the last 3 months is 249,492 and the stock's 52-week low/high is $0.412/$1.53.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

With its proposed acquisition of Lyfted Farms Inc. of Modesto, California, TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) is showing that its search for synergies continues. The company, based in Vancouver, Canada, announced the execution of a non-binding letter of intent dated May 17, 2019, to acquire the business and assets of Lyfted (http://nnw.fm/rOf1I).

TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) brings together a rapidly growing portfolio of cannabis and hemp-related brands and services, with a closed-loop ecosystem approach rooted squarely in the company’s ownership of a 196,000-square-foot, vertically integrated facility in California. The company has developed a two-year, four-phase plan aimed at developing proprietary brands and creating a self-contained ecosystem that ensures reliability, consistency, quality and scale.

Ecosystem

TransCanna’s cannabis facility in Modesto, California, is strategically located less than a three-hour drive from the majority of all major cities in the state. The tri-level building provides internal control of everything needed for the seed-to-sale cycle, from growing and manufacturing to extraction, bottling, transportation and distribution. The facility, which recently went through an US$8 million renovation, is upgraded with a premium quality HVAC system and highly insulated roof to help reduce power costs, which already are some of the lowest in California.

The company has set 2020 goal for implementation of its full-service software platform, 420 Global, which will interact with every aspect of production flow, business development and the sales process.

Growing Portfolio

Acquisitions slated to be completed in June include Goodfellas Group LLC, a full-service advertising and marketing agency for the U.S. cannabis and hemp industries. Under the deal, TransCanna will also be acquiring Daily Cannabis Goods, a pre-rolled brand with nominal start-up costs and superior SKU velocity with cannabis products available at more than 30 dispensaries throughout California.

On Deck

The company has moved to acquire organic hemp-infused CBD coconut oil Biovelle (www.Biovelle.com). Biovelle is non-GMO, vegan and gluten free, with coconut sourced from plantations in the Philippines and American grown hemp from farms in Colorado.

TransCanna has also moved to further secure a growing foothold in cannabis edibles via a non-binding letter of intent with Persuasion Brewing Co., located near the company’s flagship facility in Modesto. The goal is to establish a Persuasion Brewing division at the main facility, which will produce a variety of different CBD infusion non-alcoholic beers.

Similarly, the company has recently executed a non-binding LOI with SolDaze (Tres Ojos Naturals, LLC) to gobble up the branding asset package of this California manufacturer of cannabis-infused fruit snacks (www.soldazesnacks.com).

Management

TransCanna’s management team consists of seasoned agriculture and consumer goods-oriented veterans.

Director, CEO and Chairman James Pakulis has 30 years of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He has been on the front lines of the California cannabis industry for nearly a decade. He was CEO and chairman in 2010 of General Cannabis, Inc., which wholly owned the popular Weedmaps brand. Pakulis oversaw the growth of General Cannabis from pre-embryonic stages to over $16 million in revenue in less than two years, reaching a market cap of approximately $480 million.

Director and President Arni Johannson brings over 30 years of investing experience in the Canadian capital markets. He has built and or funded over 50 startups from around the world. He is president of Canadian Nexus Ventures and has been instrumental in providing guidance to pre- and post IPO companies, as well as guidance and oversight for corporate governance.

Stephen Giblin, board director, is an accomplished leader in the global hospitality, technology and real estate industries with a demonstrated track record of value creation. Juan Pablo Flores, independent director, is an attorney with more than 25 years of legal experience with a strong background in municipal, government, real estate, corporate and general civil law litigation.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $5.35, off by 3.60%, on 39,134 volume with 59 trades. The average volume for the last 3 months is 159,075 and the stock's 52-week low/high is $0.77/$7.79.

Recent News

chart

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Geyser Brands Inc. (TSX.V: GYSR) was featured today in the 420 with CNW by CannabisNewsWire. On Friday (May 31), the legislature in Alabama passed a bill which opens the way for legalizing medical marijuana in the state. The Assembly voted 80-19 for the bill while the Senate approved the amendments made by the House by a 27-2 vote. All that is left is for Gov. Ivey to sign the bill into law.

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.61, up 7.02%, on 6,500 volume with 4 trades. The average volume for the last 3 months is 8,848 and the stock's 52-week low/high is $0.55/$0.85.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Innovative Properties Inc. d/b/a Nabis Holdings (CSE:NAB) (OTC: INNPF) (FRA: 71P), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, this morning announced that its CEO and Director Shay Shnet and President Mark Krytiuk will present live at the VirtualInvestorConferences.com at 3:00 PM ET on Tuesday, June 4, 2019. To view the full press release, visit: http://nnw.fm/rlC8c.

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.48895, up 5.45%, on 40,182 volume with 34 trades. The average volume for the last 3 months is 181,869 and the stock's 52-week low/high is $0.392/$0.791.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that CJ Barnum, Ph.D., Director of Neuroscience, will be presenting a poster and giving a scientific talk on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, 2019.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.2711, off by 0.76%, on 8,311 volume with 77 trades. The average volume for the last 3 months is 17,710 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Also today, the company was highlighted in the Venture Breakfast Bits, by 24/7 Market News, Full press release.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.895764, off by 3.56%, on 89,808 volume with 94 trades. The average volume for the last 3 months is 105,604 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Nightfood Holdings, Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings, Inc. (NGTF).

Nightfood, Inc. (OTCQB: NGTF), the innovative ice cream company solving America’s $50 billion-dollar nighttime snacking problem, today announced Nightfood has been named a finalist in the 2019 World Dairy Innovation Awards. Nightfood was entered in four categories for the awards, and is a finalist in the following three categories:  Best Dairy Dessert, Best Ice Cream, and Best Brand. 

Nightfood Holdings, Inc. (OTCQB: NGTF), a pioneering consumer goods brand development company headquartered in Tarrytown, New York, owns Nightfood, Inc., creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts, and its wholly owned subsidiary MJ Munchies, Inc., which seeks to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. Known as “The Nighttime Snack Company,” Nightfood Inc. is focused on improving the late-night snacking choices of consumers while solving America’s $50 billion-dollar nighttime snacking problem.

Nightfood Ice Cream

Nightfood’s higher-protein and sleep-friendly ice cream won the 2019 Product of the Year Award in a survey of over 40,000 consumers. The annual Product of the Year survey, the world’s largest consumer-voted award for product innovation, is conducted by Kantar, a global leader in consumer research. In beating out the other finalists, consumers indicated that Nightfood’s one-of-a-kind innovation and unique value proposition made it a clear-cut winner in the ice cream space and a brand they were highly motivated to try. Winners of the 32-year-old award have been shown to outperform category sales performance by over 38 percent.

Less than two months since manufacturing their first pint of ice cream, Nightfood has now secured distribution in more than 13 states, and has received extensive media coverage from outlets such as USA Today, Fox Business’ Mornings With Maria, Parents Magazine, The Food Network, MarketWatch, The Washington Post, Business Insider, Bustle, and more.

With the Product of the Year award and millions in media coverage, Management has publicly stated their goal of securing nationwide distribution in over 10,000 retail outlets by March 31, 2020.

Formulated by leading sleep and nutrition experts, including America’s most prominent sleep expert, Dr. Michael Breus, Nightfood’s higher protein/higher fiber, and lower sugar ice cream delivers great ice cream taste and texture, while minimizing sleep-disruptive ingredients such as caffeine, excess sugar, and excess fat and calories. The addition of certain minerals, enzymes and amino acids, which research suggests can support sleep quality, is another bonus. Nightfood only uses hormone-free milk, is certified Kosher, and offers eight original flavors, five of which are gluten-free. Nightfood ice cream also uses all-natural sweeteners with no Erythritol, no sucralose, or other artificial sweeteners.

More than 37,000 consumers across the country have already requested coupons for the company’s newly launched Nightfood ice cream by entering a giveaway hosted at NightfoodIceCream.com which includes a chance to win a one-year supply (96 pints) plus a freezer for storage. The coupon program is being run in conjunction with PromotionPod, which has previously conducted successful campaigns for brands such as Chobani, Halo Top, and BodyArmor.

Nightfood Inc. began its nationwide rollout of Nightfood ice cream in February 2019, successfully securing placement in Meijer supermarket locations in the Midwest with a concentration around the metropolitan areas of Chicago, Detroit, Indianapolis, Columbus and Milwaukee. A distribution agreement with New England Ice Cream Corporation (NEIC) will also place Nightfood ice cream in outlets located throughout Massachusetts, Vermont, New Hampshire, Maine, Rhode Island and Connecticut.

Ice cream lovers in northern California will find Nightfood Ice Cream at various upscale, independent retail outlets in and around the San Francisco bay area serviced through a distribution agreement with Wonder Ice Cream Company, which services thousands of retail outlets from Bakersfield north to the Oregon border. Consumers can also purchase Nightfood ice cream online at BuyNightfood.com through the Company’s partnership with IceCreamSource.com.

Ice cream is now the 2nd most popular night snack choice, with almost half of all consumers reaching for ice cream after dark. According to IRI Worldwide, 44 percent of all snack consumption occurs between dinner and bedtime, representing a consumer spend of over $1 billion weekly on nighttime snacks in the U.S. alone. Market research giant Mintel recently released a report identifying nighttime specific food and beverages as one of their most “compelling and category changing” trends for 2017 and beyond.

Nightfood has developed a dynamic infographic resource that clearly illustrates the size and scope of the largely untapped nighttime snack category (http://NightSnacking.com). Americans everywhere are likely to identify with the infographic’s results that vividly illustrate late night snacking by age group, popular snack choice, and amount of money spent each week on feeding after-hour snack attacks. Available in eight delicious flavors, Nightfood ice cream can help consumers satisfy nighttime cravings in a better, healthier, more sleep-friendly way.

MJ Munchies, Inc.

MJ Munchies, Inc., was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company intends to market some of these new products under the trademarked brand name “Half-Baked” and has entered into a Letter of Intent that allows Global Consortium Inc. (OTC: GCGX) subsidiary Infused Edibles to receive an exclusive license to manufacture and distribute marijuana and CBD-infused products under the Half-Baked brand.

Management believes the Half-Baked brand will give the Company a unique and defensible competitive advantage against other recreational edible brands. The Company believes tremendous opportunities currently exist to launch successful and legally compliant products in this space, and that such opportunities will continue to grow over time.

Management Team

Nightfood founder and CEO Sean Folkson is a formerly frustrated nighttime snacker whose late-night cravings led him to seek a better solution for himself and others through the creation, marketing and distribution of the Nightfood product line. Folkson also founded internet marketing company AffiliatePros.com which provided the startup capital to launch Specialty Equipment Direct, an online distributor of floor removal equipment that quickly grew to 7-figure revenues. Folkson received a bachelor’s degree in business administration with a concentration in marketing from S.U.N.Y Albany, New York, in 1991.

Jim Christensen, vice president of Nightfood Ice Cream, is the former Vice President of Ice Cream Sales with global ice cream giant Unilever. In his over 20 years at Unilever, Jim led sales and distribution initiatives for brands such as Ben & Jerry’s, Klondike, Breyers and Good Humor. Christensen joined the Nightfood team in June of 2018 with the directive to launch Nightfood ice cream rapidly into national distribution through supermarket, drug, convenience and other channels. Understanding that the overwhelming majority of at-home ice cream consumption occurs in the hours before bed, Christensen has identified Nightfood as the next evolution in better-for-you ice cream.

CFO Mark Noffke, CPA, has over 37 years of experience as a seasoned financial and management professional. He has served as chief financial officer of several small cap public companies since 2004 where he oversaw virtually every aspect of the company’s operations, administration, customer service and human resources. Noffke has a bachelor’s degree in accounting from Valparaiso University in Indiana.

Advisory Board

The Nightfood advisory board includes Tom Morse, founder of 5-Hour Energy and Living Essentials, LLC.; Doron Stern, former vice president of marketing at Chobani and Popcorn, Indiana; restaurateur and celebrity Chef Chris Santos; Paul Jarrett, CEO of fast-growing nutrition startup BuluBox; Eric Egeland, president of Capacity Consulting Inc.; Dr. Michael A. Grandner, director/Sleep and Health Research Program at the University of Arizona; Dr. Michael Breus, sleep expert and best-selling author known to millions as The Sleep Doctor(TM); Dr. Lauren Broch, resident nutrition, sleep disorder expert and a member of the scientific advisory board.

Nightfood Holdings, Inc. (NGTF), closed the day's trading session at $0.455, up 17.15%, on 376,686 volume with 149 trades. The average volume for the last 3 months is 328,202 and the stock's 52-week low/high is $0.16/$0.92.

Recent News

chart

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. Also today, the company was named as among the companies featured on the newly announced OTCQX Cannabis Index, from OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities. Additionally, the company was highlighted today in the Venture Breakfast Bits, by 24/7 Market News

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint. 

The Company has distribution arrangements in all 10 provinces1. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs)2. As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

  • CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
  • Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
  • Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
  • Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
  • Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

1 Subject to final regulatory approval from Quebec
2 Several factors can cause actual capacity and costs to differ from estimates. See “Risks and Uncertainties” in the Company’s Q2 2019 MD&A and “Risk Factors” in the latest Annual Information Form.

Organigram Holdings Inc. (NASDAQ: OGI), closed the day's trading session at $7.43, up 8.31%, on 958,070 volume with 3,499 trades. The average volume for the last 3 months is 1,310,833 and the stock's 52-week low/high is $2.97/$8.44.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Technology and investment company SinglePoint (OTCQB: SING) today announced that, since completion of the acquisition, Direct Solar has secured $421,808 in solar installation contracts. To view the full press release, visit: http://nnw.fm/Yx62R.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed the day's trading session at $0.0118, off by 6.35%, on 3,591,742 volume with 115 trades. The average volume for the last 3 months is 3,863,756 and the stock's 52-week low/high is $0.0106/$0.068.

Recent News

chart

Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) this morning announced that its Chief Science Officer Dr. Arup Sen was featured in an interview in a special edition of Investorideas.com potcasts. To listen to the interview, visit: http://nnw.fm/8zrNS. To view the full press release, visit: http://nnw.fm/JWx2j.

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed the day's trading session at $0.557791, up 1.97%, on 165,602 volume with 138 trades. The average volume for the last 3 months is 797,260 and the stock's 52-week low/high is $0.189/$1.875.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was named today as among the companies featured on the newly announced OTCQX Cannabis Index, from OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities. Also today, the company was highlighted in a publication from FN Media Group, discussing how the cannabis industry has seen an explosion of mergers and acquisitions over the past year. Major companies have been competing amongst each other for the most attractive deals, often paying premiums in the process to make their offers more appealing.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.20, up 5.26%, on 257,881 volume with 418 trades. The average volume for the last 3 months is 574,653 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile Inc. (TSX-V:SIM / OTCQX:SYATF), a leading provider of in-vehicle communication devices, is pleased to announce the Uniden® UV350 in-vehicle mounted phablet is FirstNet Ready™, making it tested and approved for use with services on the FirstNet communications platform. Also today, the company was featured in an Investorideas.com publication discussing how the global connected cars market was valued at $73.18 Billion USD in 2018. The global connected cars market is primarily driven by high adoption in the telematics segment. Along with that, factors that have reinforced the market include trend of connectivity solutions and an increase in the need for safety & security.

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed the day's trading session at $0.35, up 3.24%, on 136,357 volume with 27 trades. The average volume for the last 3 months is 62,031 and the stock's 52-week low/high is $0.254/$0.4462.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was highlighted in a publication from Financialnewsmedia.com, examining how an estimated 64 million Americans have tried some form of CBD in the last 24 months, with nearly one out of seven using the compound every day, according to a Consumer Reports survey. Also today, the company was named as among the companies featured on the newly announced OTCQX Cannabis Index, from OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities. Additionally, the company was highlighted today in the Venture Breakfast Bits, by 24/7 Market News

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.7508, up 7.87%, on 548,802 volume with 824 trades. The average volume for the last 3 months is 1,069,140 and the stock's 52-week low/high is $1.607/$7.894.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.